Live demo · Dose synthesis · IND amendment

What dose ships when 100 mg is sub-efficacious and 300 mg triggers DLT?

Pick a dose. Smriti traverses the compound graph — efficacy, biomarker, adverse event — and returns the AI-generated recommendation with a verifiable evidence chain. Bit-identical replay against stored metadata. IND-amendment ready.

Choose a CB-209 dose arm

SAFE · 100 mg · 18% CRP · NO DLT

TOXIC · 300 mg · 38% CRP · DLT 29%

200 mg
RECOMMENDED

100 mg 200 mg 300 mg

✓

Verdict: 200 mg — MAXIMUM TOLERATED DOSE

Source documents

Protocol CB-209-001 + Troponin-T ref

Provenance score

1.00 — literal-match (2 claim spans)

Efficacy (CRP reduction)

~32% at Week 8 — meets endpoint (interpolated)

Safety (Troponin-T)

Projected below 0.10 ng/mL stopping rule

Replay anchor

call_7d3a · SHA-256 verified · bit-identical

Filed

FDA IND amendment 2024-11-22

Every dose recommendation in your trial should reconstruct itself in front of an FDA reviewer. Smriti makes that the default.

Book a 20-min call →